Clinical Remission in Severe T2-High Asthma After Biologics

Key Takeaways

• Clinical remission was reported in about one-third of a severe T2-high asthma cohort after 12 months of first biologic therapy.
• Remission required no exacerbations, no systemic corticosteroid use, and good symptom control by ACT and ACQ-6 thresholds.
• Adding a lung-function component reduced the remission proportion, and lower baseline CRP showed the most consistent association with remission.

Remission proportions were broadly similar across omalizumab, mepolizumab, and benralizumab (29%, 28%, and 37%, respectively). In adjusted analyses, lower baseline CRP was the only independent factor associated with reaching the endpoint. Remission was evaluated as a composite outcome across the first treatment year.

Clinical remission required four elements at 12 months: no exacerbations, no systemic corticosteroid use, an ACT score of at least 20, and an ACQ-6 score below 1.5. Investigators applied this composite definition at the scheduled one-year visit after biologic initiation. The added functional element required post-bronchodilator FEV1 above 80% predicted or an increase in pre-bronchodilator FEV1 from baseline above 100 mL. When the authors added that lung-function component in a sensitivity analysis, the remission rate fell to 22%.

Patients who reached remission entered treatment with more favorable baseline features than those who did not. The remission group had better pre- and post-bronchodilator lung function, lower CRP, earlier asthma onset, and less frequent smoking history. These contrasts aligned with a generally more favorable starting profile among patients who later met remission criteria. The investigators reported no clear separation in other T2 biomarkers, although FeNO was borderline higher in the remission group. Across baseline variables, CRP showed the clearest separation.

In multivariable analysis, lower baseline CRP remained the only independent predictor associated with clinical remission. The study also reported a receiver operating characteristic area under the curve of 0.65 for CRP. Its Youden index occurred at 2.3 mg/L, which the investigators presented as a modest discrimination signal rather than an actionable threshold. The ROC result reflected limited separation between remission and non-remission outcomes. After adjustment, the predictor pattern narrowed to baseline CRP alone.

This single-center retrospective cohort followed adults with severe T2-high asthma during their first 12 months of omalizumab, mepolizumab, or benralizumab treatment. The cohort came from a severe asthma clinic registry and focused on patients starting, rather than switching, biologic therapy. The investigators framed remission as a year-long composite combining symptom control, absence of exacerbations, and freedom from systemic corticosteroid use. Within that framework, lower CRP identified patients who were more likely to meet the reported endpoint in this cohort. The reported finding remained an observational association between baseline CRP and year-one composite remission.